A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
Tekijät: Vuorinen RL, Paunu N, Turpeenniemi-Hujanen T, Reunamo T, Jekunen A, Kataja V, Sintonen H, Purmonen T, Kellokumpu-Lehtinen PL
Kustantaja: INT INST ANTICANCER RESEARCH
Kustannuspaikka: Athens
Julkaisuvuosi: 2019
Journal: Anticancer Research
Tietokannassa oleva lehden nimi: ANTICANCER RESEARCH
Lehden akronyymi: ANTICANCER RES
Vuosikerta: 39
Numero: 10
Aloitussivu: 5559
Lopetussivu: 5564
Sivujen määrä: 6
ISSN: 0250-7005
eISSN: 1791-7530
DOI: https://doi.org/10.21873/anticanres.13749
Verkko-osoite: 10.21873/anticanres.13749
Tiivistelmä
Background/Aim: Tyrosine kinase inhibitors are important in the treatment of metastatic renal cell cancer (mRCC). The aim of the study was to evaluate the costs and effects of sunitinib in mRCC. Patients and Methods: A total of 81 mRCC patients who received first-line sunitinib therapy between 2010 and 2014 were recruited. Drug doses, laboratory and imaging studies, outpatient visits and inpatient stays were recorded. Health-related quality of life (HRQoL) was measured (15D- and EQ-5D - 3L questionnaires). Results: The cost of sunitinib (mean 22,268 (sic)/patient range 274 (sic) to 105,121 (sic)) covered 73% of the total costs during the treatment period. The total treatment cost was 30,530 (sic)/patient (range=1,661-111,516 (sic)). The median overall survival was 17.9 months. HRQoL decreased during treatment. Conclusion: The main cost during sunitinib treatment of mRCC was the drug itself (73% of the total costs). Drug costs and HRQoL should be considered when choosing treatment for mRCC.
Background/Aim: Tyrosine kinase inhibitors are important in the treatment of metastatic renal cell cancer (mRCC). The aim of the study was to evaluate the costs and effects of sunitinib in mRCC. Patients and Methods: A total of 81 mRCC patients who received first-line sunitinib therapy between 2010 and 2014 were recruited. Drug doses, laboratory and imaging studies, outpatient visits and inpatient stays were recorded. Health-related quality of life (HRQoL) was measured (15D- and EQ-5D - 3L questionnaires). Results: The cost of sunitinib (mean 22,268 (sic)/patient range 274 (sic) to 105,121 (sic)) covered 73% of the total costs during the treatment period. The total treatment cost was 30,530 (sic)/patient (range=1,661-111,516 (sic)). The median overall survival was 17.9 months. HRQoL decreased during treatment. Conclusion: The main cost during sunitinib treatment of mRCC was the drug itself (73% of the total costs). Drug costs and HRQoL should be considered when choosing treatment for mRCC.
Turun yliopiston Tutkimustietojärjestelmän portaali